Acorda Decides Tozadenant Isn’t Salvageable, Moves Primary Focus To Inbrija

Days after revealing seven cases of sepsis in trial participants receiving tozadenant – including five deaths – Acorda terminates development of the Phase III Parkinson’s candidate.